Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis.

IF 0.9 Q4 OPHTHALMOLOGY

Expert Review of Ophthalmology Pub Date : 2022-01-01 DOI:10.1080/17469899.2022.2114456

Joanne Thomas, Lucas Kim, Thomas Albini, Steven Yeh

{"title":"Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis.","authors":"Joanne Thomas, Lucas Kim, Thomas Albini, Steven Yeh","doi":"10.1080/17469899.2022.2114456","DOIUrl":null,"url":null,"abstract":"Introduction: Macular edema due to noninfectious uveitis is a sight-threatening complication that is routinely treated with corticosteroids. Triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere™) is an alternative treatment option for patients with non-infectious uveitis associated macular edema.Areas covered: This review describes the recently FDA approved triamcinolone acetonide injectable suspension that can be injected into the suprachoroidal space. This physiological space is between the sclera and choroid. This allows for therapeutic targeting of the retina and choroid. This review highlights published clinical trials for this novel drug preparation.Expert opinion: Suprachoroidal administration of triamcinolone acetonide has shown improvement in vision and inflammation in studies with non-infectious uveitis associated macular edema. This unique delivery method suggests the potential to decrease side effects of anterior segment exposure such as glaucoma and cataract, but head-to-head trials are needed for further study of safety and efficacy. Additionally, there are promising prospective studies underway for utilization of the suprachoroidal space for other diseases including macular degeneration, diabetic macular edema, and ocular tumors.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 3","pages":"165-173"},"PeriodicalIF":0.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438525/pdf/nihms-1832307.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17469899.2022.2114456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Introduction: Macular edema due to noninfectious uveitis is a sight-threatening complication that is routinely treated with corticosteroids. Triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere^™) is an alternative treatment option for patients with non-infectious uveitis associated macular edema.

Areas covered: This review describes the recently FDA approved triamcinolone acetonide injectable suspension that can be injected into the suprachoroidal space. This physiological space is between the sclera and choroid. This allows for therapeutic targeting of the retina and choroid. This review highlights published clinical trials for this novel drug preparation.

Expert opinion: Suprachoroidal administration of triamcinolone acetonide has shown improvement in vision and inflammation in studies with non-infectious uveitis associated macular edema. This unique delivery method suggests the potential to decrease side effects of anterior segment exposure such as glaucoma and cataract, but head-to-head trials are needed for further study of safety and efficacy. Additionally, there are promising prospective studies underway for utilization of the suprachoroidal space for other diseases including macular degeneration, diabetic macular edema, and ocular tumors.

查看原文本刊更多论文

曲安奈德注射用脉络膜上混悬液治疗葡萄膜炎引起的黄斑水肿。

简介:非感染性葡萄膜炎引起的黄斑水肿是一种威胁视力的并发症，通常用皮质类固醇治疗。曲安奈德脉络膜上注射混悬液(Xipere™)是非感染性葡萄膜炎相关性黄斑水肿患者的另一种治疗选择。涵盖领域:本综述描述了最近FDA批准的可注射到脉络膜上间隙的曲安奈德注射混悬液。这个生理间隙位于巩膜和脉络膜之间。这允许治疗视网膜和脉络膜的靶向。本文综述了已发表的这种新型药物制剂的临床试验。专家意见:在非感染性葡萄膜炎相关黄斑水肿的研究中，曲安奈德在脉络膜上给予改善视力和炎症。这种独特的给药方式可能减少前段暴露的副作用，如青光眼和白内障，但需要进一步研究安全性和有效性的头对头试验。此外，关于利用脉络膜上间隙治疗黄斑变性、糖尿病性黄斑水肿和眼部肿瘤等其他疾病的前瞻性研究也在进行中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Ophthalmology Health Professions-Optometry

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The worldwide problem of visual impairment is set to increase, as we are seeing increased longevity in developed countries. This will produce a crisis in vision care unless concerted action is taken. The substantial value that ophthalmic interventions confer to patients with eye diseases has led to intense research efforts in this area in recent years, with corresponding improvements in treatment, ophthalmic instrumentation and surgical techniques. As a result, the future for ophthalmology holds great promise as further exciting and innovative developments unfold.